UNSPSC 51371909: Dipipanone hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C24H31NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8VY00AJ0RL, chemically known as 4,4-diphenyl-6-piperidino-3-heptanone hydrochloride but more generally known as dipipanone hydrochloride, which bears US NIH Compound Identifier 13330. European Medicines Agency schedules Dipipanone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01788MIG.

Most nations, for tariff and trade purposes, schedule dipipanone hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, DIPIPANONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dipipanone hydrochloride bears US NLM identifiers UMLS ID C0770934 and NCI Concept Code C76839. SMILES: CCC(=O)C(CC(C)N1CCCCC1)(C2CCCCC2)C3CCCCC3.CL.

UNSPSC 51371909 Dipipanone hydrochloride is a Commodity code that records minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The single recent opportunity posted under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and safe drug deactivation systems rather than dipipanone hydrochloride itself, indicating a mismatch between the code's chemical designation and the work actually being bought. The county's procurement focuses on opioid-overdose-response supplies and drug disposal equipment for community health initiatives, a mission substantially different from the acquisition of a specific pharmaceutical intermediate or controlled substance. This divergence suggests the code either captures historical pharmaceutical procurement that has since shifted or receives miscoded notices from issuers unfamiliar with precise UNSPSC taxonomy in the public health domain.

Seminole County is the only issuing body supporting recent activity under this code. The IFB, posted June 30, 2026, with response due July 26, 2023, calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with a one-year renewal option and includes standard compliance requirements—drug-free workplace certification, E-Verify, workers' compensation, and commercial general liability insurance—with potential FEMA funding triggering adherence to federal environmental regulations. Geographic activity is limited to Florida based on recent records, and no other state or local jurisdictions appear in the available opportunity set. Business developers should verify whether their service or product offerings match the actual scope of work (emergency response and public health supplies) rather than the code's chemical name, and monitor for future activity suggesting whether this code genuinely reflects state and local buying patterns in pharmaceuticals or controlled substances.